Core evidence place in therapy summary for aprepitant in the prevention of chemotherapy-induced nausea and vomiting

Outcome measure	Evidence	Implications
Patient-oriented evidence
Control of acute and delayed emesis	Clear	Adding aprepitant to standard antiemetic therapy with dexamethasone plus a serotonin antagonist improves control of emesis and reduces need for rescue medication in patients receiving moderately or highly emetogenic chemotherapy
Control of nausea	Clear	Adding aprepitant to standard antiemetic therapy with dexamethasone plus a serotonin antagonist reduces symptoms of nausea in patients receiving moderately or highly emetogenic chemotherapy
Patient satisfaction	Clear	Patients more satisfied with their antiemetic therapy when aprepitant added; less impact of symptoms on daily activities
Economic evidence
Cost effectiveness	Limited	Acquisition cost of aprepitant may be partially offset by savings in overall direct costs